Nexstim Plc’s New Shares Have Been Registered in Trade Register
Company Announcement, Helsinki, 25 April 2023 at 3 PM (EEST) Nexstim Plc’s New Shares Have Been Registered in Trade Register...
Brain
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER,...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by...
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
First-ever orphan drug designation for genetically modified gamma-delta T cell therapiesThis orphan drug designation offers potential 7-year market exclusivity for...
Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment System
The FreeClimb 70 Reperfusion System, powered by the Tenzing 7 delivery catheter, enables neurointerventionalists to address critical unmet needs in...
Baycrest’s Goal Management Training Now Offered Through Telus Health’s AbilitiCBT Platform
First large-scale digital roll out of Baycrest’s Goal Management Training will support mental rehabilitation for people across Canada and the...
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of...
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and...
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19,...
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company...
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023...
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a...
$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology
Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company working to accelerate the development...
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision...